How do you approach a medically inoperable patient with clinically stage 2 grade 1 endometrioid endometrial carcinoma with heavy vaginal bleeding that is refractory to EBRT and requiring inpatient management with transfusions?

Community
Company
News
Contact Us
Sign in

Topics: Gynecologic Cancers • Endometrial Cancer

Answer from: at Academic Institution

Tough case that requires some individualized care- I’d favor brachy if not resectable.

11340

Related Questions

How long would you wait to start next-line chemotherapy in a patient recovering from grade 3 immune-mediated hepatitis secondary to lenvatinib/pembrolizumab for endometrial cancer?

What are your top takeaways in Gynecologic Cancers from ASCO 2023?

How do you manage a distal vaginal recurrence of endometrial adenocarcinoma in a patient who had adjuvant external beam and cylinder brachytherapy boost to the top 4 cm of the vaginal cuff?

How do you manage a patient with widely metastatic serous endometrial cancer whose disease is stable after completion of 6 cycles of chemotherapy + immunotherapy?

For a medically inoperable clinically-staged FIGO IA endometrial cancer with serous, clear cell or other non-endometrioid, high-risk histology treated with EBRT alone, would you cover elective lymph nodes, or treat the uterus alone?

When treating endometrial cancer patients with a combination of chemotherapy and vaginal cuff brachytherapy, when do you deliver cuff brachy?

What is your preferred adjuvant treatment for surgically staged IB dedifferentiated endometrial carcinoma, with negative SLNBx and extensive LVSI?

When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?

How would you approach the management of a women who was incidentally found to have a deeply invasive low-grade endometrial carcinoma after she underwent a supracervical hysterectomy with placement of mesh for uterine prolapse?

For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?